NEWS
ACPCC future-proofs laboratory with Cirdan partnership
The Australian Centre for the Prevention of Cervical Cancer (ACPCC), a not-for-profit organisation with 60 years of expertise in cervical cancer prevention, has partnered with Cirdan to implement a state-of-the- art laboratory information management system (LIMS) to optimise and future-proof its laboratory workflows. Implementation will occur throughout
2024, across the pathology division of ACPCC – VCS Pathology – in Melbourne. The implementation of Cirdan’s modern and unified LIMS will serve to improve ACPCC’s laboratory efficiency by more effectively managing the flow of samples and data, and ultimately creating a centralised storage of data required for quality control compliance. ACPCC’s vision and commitment is to
prevent cancer and infectious diseases through excellence in the provision of public health services supporting screening, population-based testing and vaccination. As part of its commitment, ACPCC continues to work with Australian and international partners to achieve the World Health Organization’s goal of eliminating cervical cancer as a public health problem, primarily through screening, establishment of screening and vaccination registries and laboratory strengthening. ACPCC was attracted to Cirdan’s LIMS
offering due to its ability to collect high volumes of data in a Lean and expeditious way, to help reduce the time taken for patient diagnosis. The system will provide new insights into healthcare data through its ability to modernise and standardise ACPCC’s pathology workflows and processes.
The new unified single LIMS system will integrate the functionality of various existing subsystems and will future-proof VCS Pathology by creating a completely digital environment, with effective sample and data management enhancing ACPCC’s pathology workflows.
Sysmex celebrates workplace recognition
Sysmex has been recognised in the ‘Great Place to Work’ scheme, receiving the 41st position in the ‘Best Workplaces 2024 – Large Category’ list, after being certified last November. In 2023 Sysmex UK was also recognised as a Great Place to Work for wellbeing.
These awards are obtained following
direct feedback from employees through an annual survey. Sysmex first participated in the Great Place to Work scheme in 2022, and the company is also looking forward to potential recognition in the Development and Wellbeing categories in 2024. Great Place to Work is an international
accreditation which recognises employers who create an outstanding employee experience. Every year organisations can apply for certification for being a ‘Great Place to Work’. Once an organisation is certified and, provided they meet the Best Workplaces Trust assessment requirements, they then could receive a Best Workplace recognition.
The company commented: “At Sysmex UK we prioritise the wellbeing and development of our employees, recognising that their success is fundamental to ours. We are committed to fostering a workplace culture that promotes physical, mental, and emotional wellbeing. This includes providing resources and support for maintaining a healthy work-life balance, offering opportunities for personal and professional growth, and cultivating an inclusive and supportive environment where every individual feels valued and empowered to thrive.”
Indica Labs receives FDA clearance for HALO platform
Indica Labs has announced that it received FDA clearance for HALO AP Dx, an enterprise digital pathology platform, for primary diagnosis. This 510(k) clearance allows HALO AP Dx to be utilised in conjunction with the Hamamatsu NanoZoomer S360MD Slide scanner for in-vitro diagnostic use and sets the stage for use with additional FDA-cleared slide scanners in the future.
HALO AP is an enterprise digital pathology platform that is deployed worldwide, created by Indica Labs with a comprehensive suite of diagnostic tools and features for efficient and accurate image evaluation, management, and collaboration. In the US, Indica Labs will continue to offer HALO AP for research- use-only applications and will now offer HALO AP Dx for primary diagnosis. “Our team is thrilled to achieve this FDA clearance for HALO AP Dx,” said Steven Hashagen, Founder and CEO of Indica Labs. “Indica Labs is dedicated to improving patient care by providing
12
an ideal environment for the practice of pathology that supports both current and future technologies, ensuring pathologists have the best tools available at their fingertips and are prepared for whatever the future of digital pathology holds.” Owing to the company’s commitment to open pathology, the platform is highly interoperable. HALO AP Dx users can adapt the platform to meet their needs and incorporate it into their existing laboratory workflows with ease, creating a custom-built environment for digital pathology and for a variety of pathologic specialties, even those with unique technical requirements. HALO AP Dx is flexible and can be deployed in either a cloud-based or on-premises environment, granting users freedom of choice as to how their data is stored.
JUNE 2024
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
